IA
ACAD icon

IndexIQ Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

IndexIQ Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$394K Buy
+16,272
New +$394K 0.01% 785

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

IndexIQ Advisors's ACAD Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2022: 16,272 shares worth $394K. The stake represents 0.01% of the portfolio and ranks #785 among its holdings.

263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • IndexIQ Advisors held 16,272 shares of Acadia Pharmaceuticals worth $394K as of Q1 2022.
  • Acadia Pharmaceuticals was a new IndexIQ Advisors position in Q1 2022.
  • Acadia Pharmaceuticals made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #785 holding.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.